Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Ultra Short Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while JPMorgan Ultra Short Income ETF trades at $50.44. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | JPST | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $50.78 |
52-Week Low | $10.24 | $50.40 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45, up 0.06% on the day. The technical outlook is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as a cash alternative, with institutional inflows and consistent monthly dividends. The fund focuses on high-quality, short-term bonds for income and capital preservation.
The outlook remains stable given its low-risk profile, offering a yield advantage over savings accounts. Risks include interest rate sensitivity and credit spread changes. Wall Street sentiment is positive for risk-averse investors seeking short-term income, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
